CWA Asset Management Group’s Akebia Therapeutics AKBA Stock Holding History

CWA Asset Management Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.3K	Hold	59,000	–	–	﹤0.01%	695
2026 Q1	$82K	Hold	59,000	–	–	﹤0.01%	647
2025 Q4	$95K	Hold	59,000	–	–	﹤0.01%	631
2025 Q3	$161K	Buy	59,000 +2,000	+4%	+$6.65K	0.01%	646
2025 Q2	$207K	Buy	57,000 +8,000	+16%	+$22K	0.01%	619
2025 Q1	$94.1K	Hold	49,000	–	–	﹤0.01%	589
2024 Q4	$93.1K	Hold	49,000	–	–	﹤0.01%	552
2024 Q3	$64.7K	Buy	+49,000	New	+$65.4K	﹤0.01%	562
2024 Q1	$89.7K	Hold	49,000	–	–	0.01%	524
2023 Q4	$60.8K	Hold	49,000	–	–	﹤0.01%	413
2023 Q3	$55.9K	Hold	49,000	–	–	﹤0.01%	352
2023 Q2	$44.8K	Buy	49,000 +20,000	+69%	+$19.3K	﹤0.01%	354
2023 Q1	$16.3K	Hold	29,000	–	–	﹤0.01%	320
2022 Q4	$16.7K	Hold	29,000	–	–	﹤0.01%	317
2022 Q3	$9K	Hold	29,000	–	–	﹤0.01%	301
2022 Q2	$10K	Buy	+29,000	New	+$12.2K	﹤0.01%	300

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

CWA Asset Management Group's AKBA Position: Q2 2026 in Review

CWA Asset Management Group held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 59,000 shares worth $67.3K. The position accounts for ﹤0.01% of the portfolio, ranked #695.

CWA Asset Management Group first reported a position in AKBA in Q2 2022 and has held it in 16 quarters since. The position peaked at $207K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

CWA Asset Management Group held 59,000 shares of Akebia Therapeutics worth $67.3K as of Q2 2026.
CWA Asset Management Group left its Akebia Therapeutics share count unchanged in Q2 2026.
Akebia Therapeutics made up ﹤0.01% of CWA Asset Management Group's portfolio in Q2 2026, its #695 holding.
CWA Asset Management Group first reported a position in Akebia Therapeutics in Q2 2022 and has held it in 16 quarters since.
CWA Asset Management Group's Akebia Therapeutics position peaked at $207K in Q2 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on CWA Asset Management Group's 13F filing for Q2 2026, filed 14 Jul 2026.